Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. Basilea is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.

Friday, December 01. 2017
  • Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales
  • Basilea updates its financial guidance for 2017 - improved result expected
Thursday, November 02. 2017
  • Cresemba launched by Pfizer in Spain and is now commercially available in all Top-5 EU markets
  • Marketing authorization received for Switzerland
Tuesday, October 31. 2017
Basel, Switzerland, October 31, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea's Head of Development, to succeed Prof. Kaufhold in the role of Chief Medical Officer and as a member of the Management Committee effective January 1, 2018.
Monday, October 23. 2017
Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) in the United States exceeded the threshold triggering the first sales milestone payment from Astellas Pharma Inc. ("Astellas") to Basilea in the amount of CHF 5 million.

Quick links:

Investor calendar
Upcoming events

News subscription
Press releases via e-mail

French Sunshine Act
Transparence des liens d’intérêt